Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 80Lymphoma 35Lymphoma, Large-Cell, Anaplastic 26Hematologic Diseases 21Recurrence 18Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Peripheral 14Lymphoma, T-Cell, Cutaneous 13Lymphoma, T-Cell 13Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Brentuximab Vedotin × Clear all
NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡